Previous 10 | Next 10 |
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that the Company has received a $125 million milestone payment from Nestlé Health Science related to the U.S. Food and Drug Administration approval of VOWST™ (fecal microbiota spores,...
2023-05-23 14:14:06 ET Summary Good preliminary results with a second generation product in blood bacterial infections. The Ulcerative Colitis program is still alive. Excessive cash burn in Q1 2023 explained in part by the manufacture of VOWST. Review of cost savings across th...
2023-05-22 14:49:12 ET Summary SER-109 (Vowst) was recently approved by FDA and will be launched in June with the Nestle commercial team. Most of the pipeline has failed in clinical trials. There is one active, albeit early stage clinical program, SER -155. The company bur...
Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry PR Newswire The company's MIMiC™ platform drives unprecedented insights into molecular interactions to design new biomolecules precisely tuned for therapeutic benefi...
2023-05-09 13:48:14 ET Start Time: 08:30 End Time: 09:18 Seres Therapeutics, Inc. (MCRB) Q1 2023 Earnings Conference Call May 09, 2023, 08:30 AM ET Company Participants Eric Shaff - President and CEO Terri Young - EVP, Chief Commercial and Strategy Officer ...
2023-05-09 07:04:12 ET Seres Therapeutics press release ( NASDAQ: MCRB ): Q1 GAAP EPS of -$0.57 misses by $0.02 . Seres ended the first quarter of 2023 with $106.5 million in cash, cash equivalents and investments as compared with $181.3 million at the end of 2022. ...
– VOWST ™ microbiota-based therapeutic approved for prevention of recurrence of C. difficile infection in adults following antibacterial treatment for recurrent CDI; product availability expected in June – – New SER-155 Phase 1b Cohort 1 clinical data show ...
– Tolerability profile observed supports continued development in Cohort 2, with no treatment attributed serious adverse events – – Reduction in incidences of microbiome pathogen domination provides support for intended SER-155 clinical activity – ...
2023-05-08 14:34:13 ET Seres Therapeutics ( NASDAQ: MCRB ) is scheduled to announce Q1 earnings results on Tuesday, May 9th, before market open. The consensus EPS Estimate is -$0.54 and the consensus Revenue Estimate is $1.58M (+6.0% Y/Y). Over the last 3 months, EPS e...
– Data from Phase 3 open-label single-arm study of VOWST found nearly 95% of individuals with a clinical response at 8 weeks remained free of CDI through Week 24, regardless of number of prior C. difficile infections (CDI) – – Results from ECOSPOR IV ...
News, Short Squeeze, Breakout and More Instantly...
Seres Therapeutics Inc. Company Name:
MCRB Stock Symbol:
NASDAQ Market:
Seres Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 12.2% to $0.6106 on volume of 413,566,315 shares Trinity Place Holdings Inc. (TPHS) rose 44.6% to $0.1756 on volume of 351,549,876 shares Presto Automation Inc. (PRST) rose 17.4% to...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 37.2% to $0.7466 on volume of 94,759,512 shares GameStop Corporation (GME) rose 0.0% to $46.5702 on volume of 64,189,668 shares Trinity Place Holdings Inc. (TPHS) rose 126.9% to $0....
2024-06-07 09:15:02 ET Oppenheimer analyst issues PERFORM recommendation for MCRB on June 7, 2024 07:37AM ET. The previous analyst recommendation was Outperform. MCRB was trading at $0.8531 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...